SK Discovery (006120) investor relations material

Executive summary

• 9M 2026 revenue was ₩9.786tn vs ₩7.505tn YoY; operating income was ₩330.3bn vs ₩366.8bn, while net income rose to ₩488.3bn from ₩175.5bn.

• Higher net income included ₩108.3bn gain on sale of equity-method investments and substantial derivative gains; associate impairment losses were ₩27.2bn.

• Cash and equivalents reached ₩1.524tn at quarter-end, up from ₩1.314tn at FY2025-end; total assets were ₩19.001tn and total liabilities ₩10.639tn.

Financial highlights

• Gross profit was ₩1.241tn vs ₩1.073tn YoY; operating income fell to ₩330.3bn from ₩366.8bn despite higher revenue.

• Pretax income rose to ₩608.6bn from ₩190.0bn; net income was ₩488.3bn vs ₩175.5bn, including ₩329.2bn attributable to owners vs ₩90.1bn.

• Basic EPS was ₩18,188 vs ₩4,762 YoY; diluted EPS was ₩18,151 vs ₩4,757.

• Operating cash flow was ₩118.9bn vs ₩419.0bn; investing outflow was ₩1.175tn and financing inflow ₩1.279tn.

• Cost of sales was ₩8.546tn and SG&A ₩910.4bn; derivative transaction gains of ₩534.9bn and derivative valuation gains of ₩361.0bn contributed to finance income.

Outlook and guidance

• Green Chemicals plans to expand recycled and bio-based materials, develop high-value Copolyester uses, and build a chemical-recycling value chain through RIC and FIC infrastructure.

• Life Science priorities include expanding CDMO opportunities, partnerships and open-innovation R&D; the 21-valent pneumococcal vaccine is in global Phase 3 trials.

• A medium-term shareholder policy sets minimum annual dividends of ₩1,700/share for common shares and planned share repurchases and cancellations totaling ₩60bn in 2026–28.